Furthermore, significant correlation between CD200 and PDL1 in AML T cell immunosuppression has already been shown by our group, suggesting that this combination also holds potential for further evaluation in AML immunotherapy.9 This evidence concerns the gene CD200 and acute myeloid leukemia.